Wedge Resection vs Lobectomy for Clinical Stage IA Non-Small Cell Lung Cancer With Occult Lymph Node Disease

• Published in: The Annals of thoracic surgery Vol. 115; no. 6; pp. 1344 - 1351
• Main Authors: Kneuertz, Peter J., Abdel-Rasoul, Mahmoud, D’Souza, Desmond M., Moffatt-Bruce, Susan D., Merritt, Robert E.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01-06-2023
• Subjects: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms - pathology; Lymph Nodes - pathology; Lymphadenopathy; Neoplasm Staging; Pneumonectomy; Retrospective Studies
• ISSN: 0003-4975; 1552-6259
• DOI: 10.1016/j.athoracsur.2022.08.044

Sublobar resection is increasingly performed for stage Ia non-small cell lung cancer, but pathologic lymph node upstaging remains a common clinical scenario. This study compares the long-term prognosis of patients with clinical stage Ia disease and occult lymph node disease undergoing wedge resection vs lobectomy.
The National Cancer Database was queried for patients treated with wedge resection or lobectomy for clinical stage Ia (cT1N0) non-small cell lung cancer and who were pathologically upstaged with either pN1/pN2 disease. Overall survival (OS) was compared by extent of resection using inverse probability treatment weighting–adjusted Cox regression analyses.
Of 5437 clinical stage Ia patients included, 3408 (62.7%) were found to have occult pN1 and 2029 (37.3%) to have occult pN2. Of 5437 patients, 93.5% (5082) were treated with lobectomy and 6.5% (355) underwent wedge resection. Lobectomy was associated with improved OS compared with wedge resection for patients with occult pN1 disease (median OS, 70.0 months [95% CI, 66.6-77.4] vs 36.4 months [95% CI, 24.2-45.6]; P < .001) but not for pN2 disease (median OS, 48.2.1 months [95% CI, 43.8-52.9] vs 43.7 months [95% CI, 31.2-62.4]; P = 0.24). On inverse probability treatment weighting–adjusted multivariable analysis, adjusting for demographics, comorbidities, margin status, and pathologic T and N stage, lobectomy remained associated with improved survival (adjusted hazard ratio, 0.73; 95% CI, 0.60-0.89; P = .0016).
Lobectomy is associated with improved survival in clinical stage Ia non-small cell lung cancer patients with occult lymph node disease. These data may aid the decision for completion lobectomy for patients with unanticipated N1 lymph node upstaging.